# TM CRUX European Fund

EUR factsheet November 2022



### Fund Facts as at 30/11/22

#### **Fund Objective**

The Fund aims to achieve long-term capital growth by investing primarily in equities of European companies.

#### **Launch Date**

2 November 2015

#### Structure

OEIC

#### Fund Size<sup>1</sup>

€64.6m

#### **Performance comparator**

IA Europe ex UK

#### **Fund Base Currency**

GBP

#### **Share Class Currency**

**EUR** 

#### **XD Dates**

01-Jan, 01-April, 01-July, 01-Oct

#### **Dividend Pay Dates**

28-Feb, 31-May, 31-Aug, 30-Nov

 ${}^{\mathrm{1}}\mathrm{The}$  base currency of the fund is GBP and this figure has been calculated using the fx rate as at 30.11.2022

Market Capitalisation	(%)
> €10bn	76.0
€1bn-10bn	21.6
<€1bn	0.0

Charges (%)	Initial	OCF
I Class (EUR)	Nil	1.07


Minimum Investment			
I Class (EUR)	€100		

ISIN Numbers (EUR)
GB00BYQJXG57 (I Acc)
GB00BYQJXH64 (I Inc)

Top 10 Holdings	%	Top 10 Coun- tries	%	Top 10 Sectors	%	
Novo Nordisk	6.0	France	22.1	Pharmaceuticals, Biotechnology & Life Sciences	13.8	
LVMH	4.7	Germany	16.9	Capital Goods	13.1	
Sampo	3.9	Switzerland	12.0	Software & Services	9.5	
ASML Holding	3.8	Netherlands	10.8	Semiconductors & Semiconductor Equipment	9.4	
Nordea	3.6	Denmark	7.6	Banks	8.5	
Schneider	3.5	Finland	7.6	Consumer Durables & Apparel	8.4	
Capgemini	2.8	United Kingdom	5.1	Technology Hardware & Equipment	4.3	
Nestle	2.7	United States	3.5	Diversified Financials	4.3	
Merck	2.7	Italy	2.8	Commercial & Professional Services	4.3	
Roche	2.5	Sweden	2.6	Transportation	4.1	

Total Holdings	53	Cash	2.4

Source: CRUX Asset Management.



Source: as at 30 November 2022. © 2022 FE. All Rights Reserved. Total return, Bid-bid in EUR, net income

Note: These figures refer to the past and past performance is not a reliable indicator of future results.

## TM CRUX European Fund

(Continued)



Disc Yr Perf* (%)	YTD	2021	2020	2019	2018	2017	Since launch
TM CEF I Acc EUR	-16.8%	23.6%	5.3%	26.0%	-15.2%	11.9%	32.6%
IA Europe ex UK	-11.8%	23.4%	4.4%	27.5%	-13.1%	12.8%	42.1%

Disc Yr Perf\* (Discrete Year Performance)

Source: as at 30 November 2022. © 2022 FE. All Rights Reserved. Total return, Bid-bid in EUR, net income reinvested. Discrete performance data may change due to final dividend information being received after quarter end.

Note: These figures refer to the past and past performance is not a reliable indicator of future results.

The fund slightly underperformed due to strong rallies in cyclicals and consumer discretionary where we are underweight. Performance was held back by more defensive names which trod water such as Nestle and DSM. Bright spots were seen in those reporting strong third-quarter results such as reseller SoftwareOne, microchip-maker Infineon, Siemens and ING Bank. Novo Nordisk advanced on strong results and as its new obesity drug Wegovy supply becomes more available. In terms of transactions, we disposed of Wolters Kluwer having performed strongly, leaving the group on a premium valuation, on overly optimistic expectations of both growth and margin progression, in our view. We started a new position in Teleperformance after the shares were over-sold on uncertainty over content moderation for social media platforms and employee treatment; the group has comprehensively addressed these issues. We sold Vitec Software on a fairly high multiple and re-entered IT reseller Cancom which had fallen back sharply this year on short-term supply chain issues but has a significant net cash balance and lowly valuation in our view.



James Milne **Fund Manager** 



**Richard Pease Fund Manager** 



Produced by MSCI ESG Research as of (30 November 2022)

MCSI ESG Research LLC's ("MSCI ESG") Fund Metrics and Ratings (the "information") provide environmental social and governance data with respect to underlying securities within more than 31,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of 1940. MSCI ESG materials have not been submitted to, nor received approval from, the US SEC or any other regulatory body. None of the information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information.

Important Information

Please note the views, opinions and forecasts expressed in this document are based on CRUX's research and analysis at the time of publication. Before entering into an investment agreement in respect of an investment referred to in this document, you should consult your own professional and/or investment adviser. TM CRUX European Fund (the 'Fund') is a sub-fund of TM CRUX OEIC (the 'Company'). The Company is an investment company with variable capital and is a UCITS Scheme. It is incorporated under the Open-Ended Investment Companies Regulations 2001 ('OEIC Regulations') in England and Wales under registry number IC001022. The Company is regulated by the FCA and was authorised on 10 December 2014. The FP CRUX European Fund was renamed the TM CRUX European Fund on 28 September 2019. This information is only directed at persons residing in jurisdictions where the Company and its shares are authorised for distribution or where no such authorisation is required. The KIID and Fund Prospectus and other documentation related to the Scheme, are available from the CRUX website www.cruxam. com. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested. If you invest through a third party provider you are advised to consult them directly as charges, performance and terms and conditions may differ materially to those shown on this document.

Please note: Due to rounding the figures in the holdings breakdown may not add up to 100%. Unless otherwise indicated all figures sourced from Financial Express, Datastream, State Street and CRUX Asset Management Ltd. Third party data is believed to be reliable, but its completeness and accuracy is not guaranteed.

This document has been approved under Section 21 of the Financial Services and Markets Act 2000 by CRUX Asset Management Ltd. This document is issued by CRUX Asset Management Ltd which is registered in England and Wales (Company no. 08697189) and whose registered address is 48 Pall Mall, London, SW1Y 5JG. It is authorised and regulated by the Financial Conduct Authority (FRN 623757)

These figures refer to the past and past performance is not a reliable indicator of future results.

The Authorised Corporate Director is Thesis Unit Trust Management Limited, Exchange Building, St John's Street, Chichester, West Sussex, PO19 1UP. Authorised and regulated by the Financial Conduct Authority.

